# Stemline Therapeutics, Inc. clinical trials: 23 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials with Stemline Therapeutics, Inc. as lead sponsor, 7 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Stemline Therapeutics, Inc.: 23 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/stemline-therapeutics-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 7
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 14, 2026 | NCT07873827 | KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies | Stemline Therapeutics, Inc. | Phase 1/2 | Not yet recruiting | Hematological Malignancy | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873827) |
| August 25, 2026 | NCT07785180 | A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy | Stemline Therapeutics, Inc. | Observational | Recruiting | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07785180) |
| August 25, 2026 | NCT07785154 | A Registry-study of ELZONRIS in Participants With BPDCN | Stemline Therapeutics, Inc. | Observational | Recruiting | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07785154) |
| August 14, 2026 | NCT07766018 | A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer | Stemline Therapeutics, Inc. | Phase 2 | Recruiting | Breast Cancer | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07766018) |
| November 10, 2025 | NCT07226427 | A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer | Stemline Therapeutics, Inc. | Phase 1 | Recruiting | Platinum-resistant Ovarian Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07226427) |
| October 15, 2024 | NCT06638307 | A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | Stemline Therapeutics, Inc. | Phase 1 | Recruiting | Advanced Breast Cancer | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06638307) |
| July 9, 2024 | NCT06492616 | A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Stemline Therapeutics, Inc. | Phase 3 | Active not recruiting | Breast Cancer | 4,556 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06492616) |
| June 13, 2024 | NCT06456463 | A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot... | Stemline Therapeutics, Inc. | Phase 2 | Active not recruiting | Acute Myeloid Leukemia | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06456463) |
| November 13, 2023 | NCT06126575 | A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function | Stemline Therapeutics, Inc. | Phase 1 | Completed | Hepatic Impairment | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06126575) |
| October 27, 2022 | NCT05596409 | ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study | Stemline Therapeutics, Inc. | Phase 2 | Active not recruiting | Metastatic Breast Cancer | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05596409) |
| October 3, 2022 | NCT05563220 | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast... | Stemline Therapeutics, Inc. | Phase 1/2 | Active not recruiting | Breast Cancer, Metastatic Breast Cancer | 435 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05563220) |
| May 23, 2022 | NCT05386108 | Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | Stemline Therapeutics, Inc. | Phase 1/2 | Recruiting | Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms... | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05386108) |
| May 19, 2022 | NCT05382936 | Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors | Stemline Therapeutics, Inc. | Phase 1 | Terminated | Advanced Solid Tumor | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05382936) |
| December 19, 2018 | NCT03778931 | Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Stemline Therapeutics, Inc. | Phase 3 | Completed | Breast Cancer | 478 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03778931) |
| March 23, 2017 | NCT03088527 | Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer | Stemline Therapeutics, Inc. | Phase 1 | Completed | Hormone Receptor Positive Malignant Neoplasm of Breast | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03088527) |
| January 29, 2016 | NCT02667873 | A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors | Stemline Therapeutics, Inc. | Phase 1 | Completed | Solid Tumors | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02667873) |
| January 21, 2016 | NCT02661022 | SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | Stemline Therapeutics, Inc. | Phase 1/2 | Terminated | Multiple Myeloma | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02661022) |
| January 8, 2016 | NCT02650817 | Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer | Stemline Therapeutics, Inc. | Phase 1 | Completed | Metastatic Breast Cancer | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02650817) |
| January 14, 2015 | NCT02338349 | A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor... | Stemline Therapeutics, Inc. | Phase 1 | Completed | Advanced ER+, HER2-Negative Breast Cancer | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02338349) |
| October 21, 2014 | NCT02270463 | SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission | Stemline Therapeutics, Inc. | Phase 1/2 | Terminated | Acute Myeloid Leukemia | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02270463) |
| October 20, 2014 | NCT02268253 | Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) | Stemline Therapeutics, Inc. | Phase 1/2 | Completed | Myelofibrosis, Chronic Myelomonocytic Leukemia | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02268253) |
| April 15, 2014 | NCT02113982 | Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia | Stemline Therapeutics, Inc. | Phase 1/2 | Completed | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Acute Myeloid Leukemia (AML) | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02113982) |
| March 5, 2014 | NCT02078648 | Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme | Stemline Therapeutics, Inc. | Phase 1/2 | Completed | Adult Brain Glioblastoma, Glioblastoma Multiforme | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02078648) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 8 |
| Phase 1/2 | 8 |
| Phase 2 | 3 |
| Phase 3 | 2 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 9 |
| Recruiting | 6 |
| Active not recruiting | 4 |
| Terminated | 3 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Breast Neoplasms | 8 |
| Leukemia, Myeloid, Acute | 4 |
| Blastic Plasmacytoid Dendritic Cell Neoplasm | 3 |
| Multiple Myeloma | 1 |
| Recurrence | 1 |
| Hematologic Neoplasms | 1 |
| Breast Neoplasms, Male | 1 |
| Ovarian Neoplasms | 1 |
| Brain Neoplasms | 1 |
| Neoplasms by Site | 1 |
| Neoplasms | 1 |
| Breast Diseases | 1 |
| Central Nervous System Neoplasms | 1 |
| Brain Diseases | 1 |
| Central Nervous System Diseases | 1 |
| Primary Myelofibrosis | 1 |
| Leukemia, Myelomonocytic, Chronic | 1 |
| Glioblastoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Food and beverage exporters in the United States](https://specstream.ai/data/businesses/food-and-beverage-exporters/united-states)
- [Animation studios in the United States](https://specstream.ai/data/businesses/animation-studios/united-states)
- [Orthopedics practices in the United States](https://specstream.ai/data/businesses/orthopedics-practices/united-states)
- [Drama schools in the United States](https://specstream.ai/data/businesses/drama-schools/united-states)
- [Truck parts suppliers in the United States](https://specstream.ai/data/businesses/truck-parts-suppliers/united-states)
- [Legal services firms in the United States](https://specstream.ai/data/businesses/legal-services-firms/united-states)
